ArticleInfection and drug resistance2019
Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Colistin Resistance in Critically Ill Adults: A Systematic Review of Epidemiological, Clinical, Laboratory, and Molecular Evidence.Microorganisms · 2026Review
- Clinical Characteristics, Infection Profiles, and Hospital Outcomes of Intensive Care Unit Patients Undergoing Antimicrobial Therapy with Ceftolozane/Tazobactam: A Multicentric Retrospective Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Prevalence, clinical characteristics, and antibiotic resistance of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Türkiye (2023-2025).BMC microbiology · 2026Observational
- High diversity of strain clonality and metallo-β-lactamases genes among carbapenem-resistant Enterobacterales in Taiwan.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012-2021).Heliyon · 2024Review
- Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Frontiers in immunology · 2024Article
- Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study.Infection and drug resistance · 2024Article
- Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-ResistantMicrobiology spectrum · 2022Article
- Carbapenem-ResistantInfection and drug resistance · 2022Article
- Emergence of High Prevalence of Extended-Spectrum Beta-Lactamase and Carbapenemase ProducingInfection and drug resistance · 2022Article
- Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?Folia microbiologica · 2021Review
- Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Article
- Extended-Spectrum β-Lactamase and Carbapenemase Producing Gram-Negative Bacilli Infections Among Patients in Intensive Care Units of Felegehiwot Referral Hospital: A Prospective Cross-Sectional Study.Infection and drug resistance · 2021Article
- New β-Lactam-β-Lactamase Inhibitor Combinations.Clinical microbiology reviews · 2020Review
- In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).Annals of clinical microbiology and antimicrobials · 2020Article
- Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND
methodsIn total, 300 non-duplicate isolates of
resultsErtapenem non-susceptibility was detected in 3% (n=3)
conclusionCAZ-AVB exhibited excellent activity against carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.